“…This issue of Health Policy and Technology contains an article by Darba et al that describes what they found in Spanish reports of the efficacy and safety of treatments for rare lysosomal storage diseases (LSDs) like mucopolysaccharidosis (MPS), Gaucher disease, Fabry disease and Pompe disease. [1] Based on their findings, it seems that the treatments for LSDs work to differing degrees in different subgroups and that the evidence of their effectiveness varies substantially. The authors note that new methods to assess effectiveness are needed since the current methods will not be very feasible in cases where just one subgroup of patients with a rare disease represents the entire target population.…”